susan o'connor

Responsible for growing innovative businesses using unique expertise at the intersection of science and wellness. Specialty in quantitative analytics and commercial strategy for science-based, health and wellness innovations ranging from pharmaceuticals, healthtech and wellness. Expertise in business strategy, scalable go-to-market models and evidence-based strategies.

P&L accountability for Lyrica and Dynastat that generated profitable, sales growth of 7% to $400 million through targeted investment, digital innovation, integrated-marketing promotion, social media and retail programs, while developing talent and marketing capabilities.

P&L accountability that generated profitable, sales growth of 14% to $300 million through data-driven, portfolio and brand strategy that targeted investment to high-value countries and sectors, while creating brand differentiation through insight-based campaigns that grew market-leading share for Lyrica and Enbrel.

Managed operations for C-Suite Executive Team supporting strategy implementation, team effectiveness to ensure financial delivery of $14 billion sales target, and communications to the Board of Directors and Investors.

Led cross-functional, global team that created digital and public relations campaign empowering consumers to initiate treatment through the retail channel that acquired new users and increased iconic brand sales by 3%.

Led cross-functional, global team that created science-based, holistic portfolio strategy for Women’s Health based on unique customer insights, that defined new product and business development priorities, with sales potential of $250-600 million. Managed global marketing leaders accountable for growing sales for Premarin, Viagra and Toviaz.